



I am participating in the **RAMPART** clinical trial.

RAMPART is a study investigating two new immunotherapy treatments in patients who have had surgery to remove their kidney cancer. The treatments are drugs called **durvalumab** and **tremelimumab**. In RAMPART durvalumab is given alone or in combination with tremelimumab.

In the event of a medical emergency or hospital admission please present this card. The main contact for information on the study is the study doctor whose contact details appear on this card. You can also contact the research team during normal office hours.

Study Nurse : _____
9am – 5pm Mon-Fri ☎ : _____

RAMPART Study

Hospital Name: _____
Patient N°: _____
Patient's Name : _____
Trial Arm: _____
Study Doctor : _____
9am – 5pm Mon-Fri ☎ : _____
Out of hours ☎ : _____

Patients are randomised to one of three treatment arms listed below.

Arm A: active monitoring for one year

Arm B: durvalumab 4 weekly for one year

Arm C: durvalumab 4 weekly for one year plus tremelimumab (cycles 1 and 2 only)

Appointment times

Visit	Date	Time
Day 1		
Week 2		
Week 4		
Week 6		
Week 8		
Week 12		
Week 16		

Visit	Date	Time
Week 20		
Week 24		
Week 28		
Week 32		
Week 36		
Week 40		
Week 44		
Week 48		